NCT04901078 - A Phase 1 Study Investigating the Safety, Tolerability and Pharmacokinetics of KNX100 in Healthy Volunteers | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 7, 2022

Primary Completion Date

September 30, 2023

Study Completion Date

September 30, 2023

Conditions

Healthy Volunteer StudyOpioid-use Disorder

Interventions

DRUG

KNX100

KNX100 will be provided in capsule form as 5, 25 and 100 mg capsules for oral administration. Study drug will be encapsulated in hydroxypropyl methylcellulose (HPMC) dark green opaque size 0 capsules and packaged in 100 mL high density polyethylene (HDPE) bottles with polypropylene (PP) twist-off closures.

Trial Locations (1)

3004

Nucleus Network, Melbourne